Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing

In November 2013, the US Food and Drug Administration (FDA) sent a warning letter to 23andMe, Inc. and ordered the company to discontinue marketing of the 23andMe Personal Genome Service (PGS) until it receives FDA marketing authorization for the device. The FDA considers the PGS as an unclassified...

Descripción completa

Detalles Bibliográficos
Autores principales: Yim, Seon-Hee, Chung, Yeun-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korea Genome Organization 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330248/
https://www.ncbi.nlm.nih.gov/pubmed/25705152
http://dx.doi.org/10.5808/GI.2014.12.4.151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330248/
https://www.ncbi.nlm.nih.gov/pubmed/25705152
http://dx.doi.org/10.5808/GI.2014.12.4.151

Ejemplares similares